Cell and Gene Therapy Market Size, Share, Growth, and Industry Analysis, By Type (Rare Diseases,Oncology,Hematology,Cardiovascular,Ophthalmology,Neurology,Other Therapeutic Classes), By Application (Pharmaceutical and Biotechnology Companies,Research and Academic Institutions,Contract Research Organizations (CROs),Hospital,Others), Regional Insights and Forecast to 2035

Cell and Gene Therapy Market Overview

The global Cell and Gene Therapy Market size is projected to grow from USD 29319.8 million in 2026 to USD 34125.31 million in 2027, reaching USD 114900.32 million by 2035, expanding at a CAGR of 16.39% during the forecast period.

The Cell and Gene Therapy Market has grown into one of the most advanced areas of modern medicine, with over 76 approved therapies worldwide as of 2023. More than 3,900 gene therapy clinical trials are ongoing globally, with 57 % focused on oncology and 18 % on rare diseases. Cell therapies represent approximately 42 % of pipeline programs, while gene therapies account for 58 %. By therapeutic class, oncology dominates with 46 % of active trials. More than 2 million patients worldwide have received treatment through cell and gene therapy programs, confirming its expanding role in global healthcare systems.

The United States leads the Cell and Gene Therapy Market, accounting for nearly 48 % of global clinical trials. More than 2,000 gene therapy programs are currently in the U.S. pipeline, with 61 % targeting cancer and hematological conditions. The FDA approved 5 new therapies in 2023, bringing the total approved in the country to 29. Over 400,000 patients in the U.S. have been treated with various cell and gene therapy products. Academic institutions contribute significantly, with more than 120 universities and research hospitals involved in ongoing trials, reinforcing the U.S. leadership in the Cell and Gene Therapy Market Outlook.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Oncology programs represent 46 % of active clinical trials globally.
• Major Market Restraint: High therapy cost restricts access for nearly 38 % of eligible patients.
• Emerging Trends: Non-oncology applications grew to 43 % of global trials in 2024.
• Regional Leadership: North America accounts for 48 % of global cell and gene therapy development.
• Competitive Landscape: Top five companies hold 52 % of commercial therapy launches worldwide.
• Market Segmentation: Rare disease programs account for 18 % of global trials.
• Recent Development: Over 79 gene therapy trials were initiated in Q1 2025 alone.

Cell and Gene Therapy Market Latest Trends

The Cell and Gene Therapy Market Trends reflect accelerating scientific advancements and global adoption. As of 2023, there were 76 approved products worldwide, with oncology representing 46 % of clinical activity. Rare diseases accounted for 18 %, and hematology programs reached 15 %. Over 79 new gene therapy trials were launched in the first quarter of 2025, with 57 % in oncology and 26 % in rare diseases.

Non-oncology applications are also gaining traction, rising from 41 % in 2022 to 43 % in 2024. By technology type, autologous therapies represent 62 % of commercial approvals, while allogeneic therapies account for 38 %. Manufacturing capacity has expanded, with over 120 dedicated facilities worldwide and 55 % concentrated in North America and Europe.

Patient access continues to grow, with more than 2 million individuals treated worldwide through approved or investigational therapies. Hospitals represent 33 % of end-user adoption, while pharmaceutical and biotech companies contribute 47 % of development pipelines.

Digitalization is shaping manufacturing, with automation integrated into 35 % of facilities. These trends highlight opportunities for expanding applications, boosting access, and reinforcing growth highlighted in the Cell and Gene Therapy Market Analysis and Cell and Gene Therapy Market Forecast.

Cell and Gene Therapy Market Dynamics

The Cell and Gene Therapy Market Dynamics are shaped by a surge in approved therapies, accelerating clinical pipeline expansion, financing fluctuations, and evolving regulatory breakthroughs. As of end-2023, 76 cell and gene therapy products have been launched globally, a more than twofold increase since 2013. In the first quarter of 2025 alone, 79 new gene therapy trials were initiated—57 % targeting oncology—while non-genetically modified cell therapy trials for non-oncology indications rose to 74 %, up from 58 % the previous quarter. With over 3,900 gene therapy clinical trials ongoing worldwide, these factors signal powerful drivers, nuanced restraints, and profound Cell and Gene Therapy Market Opportunities shaping the Cell and Gene Therapy Market Outlook.

DRIVER

"Rising Oncology and Rare Disease Programs"

Oncology represents 46 % of active clinical trials, and rare diseases cover 18 % of development pipelines. With more than 10 million cancer-related deaths annually, the demand for innovative treatments is unprecedented. By 2024, over 2,000 oncology trials were in progress globally, accounting for nearly half of the market. Rare diseases, which affect more than 400 million people worldwide, represent a growing segment of clinical activity. The FDA alone approved 5 oncology-related therapies in 2023. These factors underline oncology and rare diseases as the strongest drivers of Cell and Gene Therapy Market Growth.

RESTRAINT

"High Costs Limiting Patient Access"

Therapy affordability restricts access for 38 % of eligible patients globally. Cell and gene therapies require complex manufacturing, with autologous treatments averaging production cycles of 2–3 weeks. Approximately 42 % of healthcare providers cite cost as a barrier to adoption. In developing regions, fewer than 15 % of patients who qualify can access these treatments. Hospitals report that 28 % of programs face reimbursement challenges. These issues slow adoption despite clinical success, positioning cost as a significant restraint in the Cell and Gene Therapy Market Outlook.

OPPORTUNITY

"Expanding Global Clinical Trials"

There are over 3,900 active clinical trials in cell and gene therapy, with Asia-Pacific contributing 29 %. China alone has more than 600 active clinical programs, while Europe hosts 850 trials across 22 countries. North America dominates with 48 %, driven by the U.S. pipeline of more than 2,000 active projects. Patient enrollment expanded by 22 % in 2024, bringing total participants above 400,000. These figures reflect a surge in R&D and international collaborations, offering strong Cell and Gene Therapy Market Opportunities.

CHALLENGE

"Complex Manufacturing and Supply Chain Constraints"

Over 120 specialized facilities exist worldwide, but supply limitations affect 33 % of production. Autologous therapies, representing 62 % of approvals, require individualized processes, creating logistical bottlenecks. Nearly 35 % of manufacturers report raw material shortages, particularly viral vectors. Delivery timelines extend by 8–12 weeks for 27 % of therapy providers. These supply-side challenges hinder scalability, making manufacturing complexity one of the most pressing issues in the Cell and Gene Therapy Market Forecast.

Cell and Gene Therapy Market Segmentation

The Cell and Gene Therapy Market Segmentation spans therapeutic types and applications. Oncology dominates with 46 % of clinical trials, followed by rare diseases at 18 %, hematology at 15 %, cardiovascular at 6 %, ophthalmology at 5 %, neurology at 4 %, and other therapeutic classes covering 6 %. By application, pharmaceutical and biotechnology companies account for 47 %, research and academic institutions for 28 %, CROs for 12 %, hospitals for 9 %, and other users for 4 %. These figures illustrate diversified adoption highlighted in the Cell and Gene Therapy Industry Report.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Rare Diseases: Rare diseases account for 18 % of global programs. Over 400 million people worldwide suffer from more than 7,000 rare conditions. By 2024, over 700 clinical trials were targeting rare diseases, with 26 % initiated in the last two years. Genetic disorders such as muscular dystrophy and hemophilia dominate. Pediatric rare disease programs represent 12 % of activity. With only 5 % of rare diseases having approved therapies, this segment represents strong Cell and Gene Therapy Market Opportunities.
• Oncology: Oncology dominates with 46 % of global trials. Over 2,000 cancer-related trials are underway, with hematological cancers representing 28 % of them. CAR-T therapies lead, accounting for 61 % of approved oncology programs. Solid tumor programs now represent 39 %, up from 33 % in 2022. With cancer affecting more than 19 million new patients annually, oncology drives the Cell and Gene Therapy Market Growth.
• Hematology: Hematology contributes 15 % of the market. Over 600 trials globally target conditions like sickle cell disease and beta-thalassemia. Hematological disorders affect more than 300 million people worldwide, with 22 % of pipeline programs focused on curative therapies. CRISPR-based programs increased to 18 % of hematology projects in 2024. These figures position hematology as a critical component of the Cell and Gene Therapy Market Analysis.
• Cardiovascular: Cardiovascular diseases represent 6 % of the market. More than 200 trials are ongoing for conditions such as heart failure and ischemic disease. Cardiovascular disorders affect over 500 million patients globally, yet gene therapy penetration remains below 10 %. Cell-based regenerative treatments account for 62 % of cardiovascular programs. With rising global prevalence, cardiovascular disease remains an important growth area in the Cell and Gene Therapy Market Insights.
• Ophthalmology: Ophthalmology represents 5 % of global activity. More than 150 trials target diseases such as retinitis pigmentosa and macular degeneration. Gene therapies address approximately 8 % of the 36 million people worldwide suffering from blindness. By 2024, ophthalmology-related cell and gene therapy programs increased by 12 % year-on-year. This area continues to expand within the Cell and Gene Therapy Industry Analysis.
• Neurology: Neurology accounts for 4 % of development programs. More than 120 trials are underway for conditions like ALS, Parkinson’s disease, and Alzheimer’s. Neurological disorders affect over 1 billion people worldwide, yet fewer than 10 approved therapies exist. Cell-based approaches represent 58 % of neurology programs, while gene therapies cover 42 %. These data highlight significant unmet demand in the Cell and Gene Therapy Market Report.
• Other Therapeutic Classes: Other therapeutic classes make up 6 % of the pipeline. These include dermatology, musculoskeletal disorders, and infectious diseases. More than 250 trials are ongoing in these categories. Skin disorders, affecting over 900 million people globally, account for 14 % of “other” programs. Musculoskeletal indications represent 10 %, while infectious disease accounts for 8 %. This segment highlights emerging opportunities in the Cell and Gene Therapy Market Outlook.

BY APPLICATION

• Pharmaceutical and Biotechnology Companies: Pharma and biotech companies dominate with 47 % of activity. More than 250 organizations worldwide are actively developing therapies, with the top 10 firms accounting for 36 % of commercialized programs. These companies manage over 2,000 clinical trials, primarily in oncology and rare diseases. Pharma partnerships with CROs increased by 22 % in 2024, reinforcing industry leadership.
• Research and Academic Institutions: Research and academic institutions represent 28 % of global trials. Over 120 universities and research hospitals in the U.S. and Europe are engaged in programs. Academic facilities conduct 40 % of early-stage studies, particularly in rare diseases. Universities contribute more than 15,000 enrolled patients annually. These institutions remain critical in the Cell and Gene Therapy Industry Report.
• Contract Research Organizations (CROs): CROs account for 12 % of global activity. More than 80 CROs worldwide support clinical research, with 60 % engaged in Phase II/III programs. CRO involvement has grown by 18 % since 2022. CROs play a pivotal role in scaling trials for pharmaceutical partners, underscoring their role in the Cell and Gene Therapy Market Analysis.
• Hospitals: Hospitals represent 9 % of adoption, with over 500 institutions worldwide delivering therapies directly to patients. In North America alone, 220 hospitals are certified treatment centers. Hospitals contribute 33 % of therapy administration. These facilities also participate in 12 % of active clinical trials, reinforcing their role in the Cell and Gene Therapy Market Insights.
• Others: Other end-users account for 4 % of market participation. This includes non-profit organizations and government-led initiatives. Over 50 government programs worldwide support patient access, covering approximately 100,000 patients annually. These stakeholders provide critical infrastructure to support the Cell and Gene Therapy Market Forecast.

Regional Outlook for the Cell and Gene Therapy Market

The Cell and Gene Therapy Market Regional Outlook demonstrates strong geographic differences, with North America leading at 48 % of global share, Europe following at 23 %, Asia-Pacific contributing 19 %, and the Middle East & Africa holding 10 %. North America’s dominance comes from more than 2,000 active clinical trials and 29 approved therapies, while Europe drives growth with 850+ trials across 22 countries. Asia-Pacific contributes over 600 trials in China and 250 programs in Japan and South Korea, supported by 25 specialized manufacturing facilities. Meanwhile, the Middle East & Africa expand patient access through 60 treatment centers across 12 countries, highlighting growing Cell and Gene Therapy Market Opportunities in emerging regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America represents 48 % of global market share. The U.S. leads with more than 2,000 active trials and 29 approved therapies. Canada contributes with 85 ongoing programs in rare diseases and oncology. More than 220 hospitals in the U.S. are certified centers for administering therapies. North America hosts 55 % of global manufacturing facilities, with over 60 specialized centers. Patient enrollment reached 200,000 across clinical programs in 2024. These metrics confirm North America’s dominance in the Cell and Gene Therapy Market Growth.

EUROPE

Europe holds 23 % of the market. Over 850 trials are ongoing across 22 countries, with the UK, Germany, and France accounting for 60 % of activity. More than 20 therapies are approved in Europe, covering oncology, hematology, and rare diseases. Europe has 30 % of global manufacturing, with 35 specialized facilities. Patient enrollment exceeded 100,000 in 2024. The EU also funds more than 40 programs annually, supporting R&D. These figures highlight Europe’s importance in the Cell and Gene Therapy Market Forecast.

ASIA-PACIFIC

Asia-Pacific contributes 19 % of global share. China leads with 600 active trials, while Japan and South Korea account for another 250. India has over 150 programs underway. The region has 25 manufacturing facilities, covering 20 % of global capacity. Patient enrollment exceeded 70,000 in 2024. APAC governments support over 50 initiatives, particularly in oncology and rare diseases. These trends show Asia-Pacific’s strong role in the Cell and Gene Therapy Market Opportunities.

MIDDLE EAST & AFRICA

The Middle East & Africa represent 10 % of the market. More than 120 trials are ongoing, primarily in Israel, Saudi Arabia, and South Africa. Over 15 therapies are approved in the region. Government partnerships support access for more than 50,000 patients annually. Hospitals in MEA administer therapies in 60 centers across 12 countries. Manufacturing is limited, with 10 facilities supporting regional programs. These figures highlight MEA’s emerging role in the Cell and Gene Therapy Industry Analysis.

List of Top Cell and Gene Therapy Companies

• Novartis AG
• Sibiono GeneTech Co. Ltd.
• Kite Pharma, Inc.
• Pfizer, Inc.
• Spark Therapeutics, Inc.
• Organogenesis Holdings Inc.
• Kolon TissueGene, Inc.
• RENOVA THERAPEUTICS
• Orchard Therapeutics plc.
• Amgen Inc.
• Shanghai Sunway Biotech Co Ltd.
• bluebird bio, Inc.
• Dendreon Pharmaceuticals LLC.
• Vericel Corporation
• ViroMed Co Ltd
• Human Stem Cells Institute
• Fibrocell Science, Inc.

Novartis AG: holds 14 % of global share, leading in oncology therapies.

Kite Pharma, Inc.: maintains 12 % share, specializing in CAR-T treatments.

Investment Analysis and Opportunities

The Cell and Gene Therapy Market attracts substantial investment across global regions. Over $25 billion equivalent was invested in 2023 across 400 projects worldwide. Asia-Pacific accounted for 29 % of new capital allocation, while Europe attracted 23 %. North America continued to lead with 48 %, hosting 120 new projects. Investment is concentrated in oncology (46 % of trials) and rare diseases (18 %). Contract manufacturing facilities increased by 15 % in 2024, bringing the global total to 120 sites. Patient enrollment in trials grew by 22 %, expanding access for more than 400,000 patients. Partnerships between pharma and biotech increased by 18 % in 2024. These figures highlight strong Cell and Gene Therapy Market Opportunities for global stakeholders.

New Product Development

Innovation in the Cell and Gene Therapy Market continues to accelerate. More than 76 products are approved globally, with 12 new approvals in 2023 alone. Oncology therapies accounted for 46 % of launches, rare diseases for 18 %, and hematology for 15 %. CRISPR-based therapies represent 22 % of pipeline development, up from 15 % in 2022. By 2025, over 50 next-generation therapies are expected to reach late-stage trials. Digital manufacturing supports 35 % of facilities, improving efficiency. Autologous products represent 62 % of approvals, but allogeneic approaches grew to 38 %. These advances underscore innovation as central to Cell and Gene Therapy Market Trends.

Five Recent Developments

• In 2023, 5 new therapies were FDA-approved in the U.S.
• In 2023, CRISPR-based programs rose to 22 % of pipeline projects.
• In 2024, global trial enrollment expanded to 400,000 patients.
• In 2024, Asia-Pacific surpassed 600 active clinical trials in China.
• In 2025, over 79 new gene therapy trials were initiated globally in Q1.

Report Coverage of Cell and Gene Therapy Market

The Cell and Gene Therapy Market Report covers therapeutic type, application, region, and competitive analysis. By type, oncology leads with 46 %, rare diseases represent 18 %, hematology 15 %, cardiovascular 6 %, ophthalmology 5 %, neurology 4 %, and other classes 6 %. By application, pharma and biotech companies dominate with 47 %, research and academic institutions account for 28 %, CROs hold 12 %, hospitals cover 9 %, and others represent 4 %. Regionally, North America leads with 48 %, Europe with 23 %, Asia-Pacific with 19 %, and MEA with 10 %. Top companies such as Novartis and Kite Pharma collectively hold 26 % of share. With over 3,900 clinical trials and 76 approved therapies, the report highlights opportunities, drivers, restraints, and challenges shaping the Cell and Gene Therapy Market Insights and Cell and Gene Therapy Market Forecast.

Cell and Gene Therapy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 29319.8 Million in 2026
Market Size Value By	USD 114900.32 Million by 2035
Growth Rate	CAGR of 16.39% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Rare Diseases Oncology Hematology Cardiovascular Ophthalmology Neurology Other Therapeutic Classes By Application : Pharmaceutical and Biotechnology Companies Research and Academic Institutions Contract Research Organizations (CROs) Hospital Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample